daunorubicin has been researched along with su 11248 in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Bainbridge, T; Cherrington, JM; Heinrich, MC; McGreevey, L; O'Farrell, AM; Schittenhelm, M; Town, AR; Yee, KW | 1 |
| Altman, J; Kuzel, T; Parajuli, R; Perdekamp, M; Tallman, M | 1 |
| Geisberg, C; Pentassuglia, L; Sawyer, DB | 1 |
2 review(s) available for daunorubicin and su 11248
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Cardiac side effects of anticancer treatments: new mechanistic insights.
Topics: Anthracyclines; Antibiotics, Antineoplastic; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Daunorubicin; Doxorubicin; Heart Failure; Humans; Indoles; Myocardial Contraction; Myocytes, Cardiac; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib; Trastuzumab | 2012 |
2 other study(ies) available for daunorubicin and su 11248
| Article | Year |
|---|---|
Synergistic effect of SU11248 with cytarabine or daunorubicin on FLT3 ITD-positive leukemic cells.
Topics: Antineoplastic Agents; Cell Division; Cell Line; Cell Line, Tumor; Cytarabine; Daunorubicin; Drug Synergism; Humans; Indoles; Intracellular Signaling Peptides and Proteins; Leukemia; Pyrroles; Sunitinib; Zinc Fingers | 2004 |
Renal cell carcinoma and acute promyelocytic leukemia: a nonrandom association?
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Colonic Neoplasms; Colonic Polyps; Cytarabine; Daunorubicin; Doxorubicin; Female; Humans; Idarubicin; Indoles; Kidney Neoplasms; Leukemia, Promyelocytic, Acute; Lung Neoplasms; Male; Mercaptopurine; Methotrexate; Middle Aged; Neoplasms, Second Primary; Pyrroles; Remission Induction; Sunitinib; Time Factors; Tretinoin | 2010 |